Hidradenitis suppurativa (HS), a chronic, inflammatory, relapsing disease of the 
apocrine glands in the skin, commonly occurs in women aged 20 to 40 years. 
Patients typically present with discomfort and/or itching associated with 
papules or nodules that may recur and lead to abscess formation and sinus 
tracts. Recent reports have demonstrated that adalimumab, a tumor necrosis 
factor (TNF) antagonist, may be effective in the treatment of patients with HS 
who have failed conventional therapy. The authors describe 3 patients who 
experienced the resolution of skin lesions associated with HS after treatment 
with adalimumab. The patients found this treatment to be convenient, as they 
could administer the therapy at home, and 1 patient was able to avoid surgical 
intervention through use of TNF-antagonist therapy. Adalimumab may resolve 
symptoms of HS when conventional therapy fails. More studies are necessary to 
investigate the efficacy and safety of adalimumab for the treatment of HS.